Sign in to auto-apply
Stillingsbeskrivelse
Researcher in Immunotherapy of cancer
The Section for Cellular Therapy counts 40 employees split in a clinical ward (Clean rooms and GMP facility) and the Translational Research Unit (15 employees, 2PIs), which is developing pre-clinical solutions in cancer immunotherapy (celltherapy.no). We have produced the first Norwegian CAR molecule, anti-CD37CAR (Köksal, Dillard et al. 2019, Caulier et al. 2024). Our Unit has the capacity to run full pre-clinical validations of TCR and CAR molecules: Radium-1 TCR was also the first ever tested TCR in an academic clinical trial in Scandinavia (Radium-1 TCR, NCT03431311; Maggadottir et al. 2024). Our discoveries have led to the establishment of two biotechs: Ultimovacs and Zelluna AS. We are located at the Oslo Cancer Cluster Incubator (https://occincubator.com/), next to the Radium Hospital, which represents an excellent environment for innovative-oriented development.
One researcher 100 % position in Immunotherapy of cancer: “4KAPAI: Fourth generation-K101CAR-based pancreatic ductal adenocarcinoma Immunotherapy” is available for a duration of three years. The project is supported by Norwegian Cancer Society.
Starting date latest September 2026.
Project description:
Chimeric Antigen Receptor (CAR) therapies have demonstrated remarkable clinical efficacy in otherwise fatal cancers; however, their therapeutic success has so far been limited to a narrow range of tumour types. K101CAR, which targets the MUC16 antigen, represents a promising strategy for the treatment of pancreatic cancer.
The aim of this project is to enhance the expression and performance of K101CAR using a fourth‑generation CAR design. By implementing a virus‑free transfection system, the project seeks to generate a product of superior quality, improved safety, and greater translational potential.
Krav
- The candidate must hold a PhD degree in a relevant scientific field and already have postdoctoral experience in immunology or immunotherapy.
- Knowledge and practical experience in immune cell culture (PBMC isolation, primary T‑cell manipulation, and functional assays) are mandatory and must be documented.
- Knowledge and practical experience in immunological methods (flow cytometry, ELISA) are mandatory and must be documented.
- Knowledge and practical experience in animal experimentation (FELASA‑C or equivalent certification) are mandatory and must be documented.
- The candidate should be hard‑working, independent, and ambitious.
- We seek someone mature and responsible, capable of driving the project at the bench, organizing meetings with partners in 4KAPAI, and disseminating results.
Ferdigheter
Erfaring
senior